X

Drug Profile

Research programme: anti-CD19 CAR T cells therapies - Kyverna Therapeutics

Alternative Names: Anti-CD19 CAR T Cellular Therapies - Kyverna Therapeutics

Latest Information Update: 09 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator National Institutes of Health (USA)
Developer Kyverna Therapeutics; National Institutes of Health (USA)
Class CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Autoimmune disorders

Most Recent Events

03 Jan 2022 Kyverna Therapeutics in-licenses anti-CD19 chimeric antigen receptor T-cell constructs from the National Institutes of Health
03 Jan 2022 Early research in Autoimmune disorders in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com